Stopping bad stem cells could block deadly cancers


Dr. Bruce Hensel: courtesy Drbrucehensel.com

As a former TV journalist who specialized in covering health and medical news I have long lamented the fact that there are fewer and fewer specialist health reporters in TV today, and even fewer who are doing really good in-depth stories. Happily NBC TV news in Los Angeles has Dr. Bruce Hensel, a veteran reporter who continues to do high quality reporting on complex topics.

One recent example, and here’s why it caught my eye, is the piece he did on some promising research being done by Dr. Dennis Slamon and his team at UCLA. (they have two Disease Team awards from us) They are looking at, as Dr. Hensel put it: “at how they can block bad stem cells that may lead to fatal cancers.” The team hope to start clinical trials on this therapy in the next few months. We are funding that work.

 It was a long and detailed report, by local TV news standards, with a lot of depth and a great deal of care in not raising hopes too high.

We often talk about the importance of new media and social media in reaching a new and wider audience, but this story is an example that if you want to reach a lot of people all at once, there is still no substitute for TV news.

Of course, I might be biased.

kevin mccormack

Mesenchymal type stem cells function more like a drugstore than a source of direct repair

The most common type of stem cell used in clinical trials today is the mesenchymal stem cell (MSC) found in bone marrow and fat. The federal web site, clinicaltrials.gov lists a few hundred MSC trials. A pair of news stories on the web this morning detail why MSCs are so versatile, but also why they have limitations.

Internal Medicine News posted a summary of the presentation CIRM grantee Jan Nolte of the University of California, Davis, made at the World Stem Cell Summit last month. She noted that when the problem is tissue damage, MSCs secrete factors that stimulate the growth of new blood vessels, recruit the patient’s own organ-specific stem cells to the site of damage, and reduce the inflammation in the area to promote healing.

But she also noted that MSCs do not make an organ or grow new replacement tissue themselves, that we need embryonic stem cells to do that. She provided a great quote on what MSCs do well:

They can become paramedics or supercharged drugstores to take these factors that we want them to deliver into the damaged or dying tissue.

Nolta heads a group that has two CIRM Disease Teams hoping to take advantage of these skills of MSCs to treat Huntington’s disease and limb ischemia.

The second news report through the service EurekAlert gave further evidence for one method MSC’s lend a helping hand, and a possible method for strengthening their grip. Earlier reports have suggested that MSCs may help cells by transferring some of their mitochondria to the damaged tissue. Since mitochondria are the energy houses that help power cells, a few extra should help damaged tissue.

Now, a team at CSIR-Institute of Genomics and Integrative Biology in Delhi, India, has published in EMBO a study that showed that in the presence of a certain protein the MSCs were more efficient in lending damaged cells needed mitochondria. They engineered MSCs to produce more of that protein and sure enough, in a mouse model of asthma, they had more therapeutic benefit. The news service quoted a member of the team, Anurag Agrawal:

The introduction of mitochondria into damaged cells has beneficial effects on the health of cells and, in the long term, we believe that mesenchymal stem cells could even be engineered to create more effective therapies for lung disease in humans.

I believe combining the power of stem cell science and gene therapy is going to produce some of the most dramatic early success stories in our field. So, it is nice to see more of the rational for this explained in public venues.

Don Gibbons